Lorlatanib

Phase 3Small molecule

Pfizer

Lorlatanib is one of 12 small molecule programs targeting Advanced Malignancies. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced MalignanciesActive, not recruiting

Advanced MalignanciesPhase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Advanced Malignancies

#DrugCompanyPhaseTrials

Talzenna

Pfizer

Phase 3

1 2

Bavencio

EMD Serono

Phase 3

3 3

Alimta

GGynecologic Oncology Group

Phase 3

1 4

Inlyta

PPrism Pharmaceuticals

Phase 3

1 5

Utomilumab

Pfizer

Phase 3

3 6

PF04518600

Pfizer

Phase 3

1 7

Versed

CConrado Roberto Hoffmann Filho

Phase 1

2 8

Novonorm

GGemini Therapeutics, Inc.

Phase 1

1 9

Lorlatanib

Pfizer

Phase 3

1 10

Drospirenone

EExeltis France

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Advanced Malignancies

NCT05059522

Clinical

Trials by Indication[1]

Advanced Malignancies1 trial

AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED AVELUMAB CLINICAL STUDIES.

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT05059522·77 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lorlatanib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lorlatanib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lorlatanib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Lorlatanib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Advanced Malignancies1 trial

References

Drug Info

Quick Facts

Related News